Pfizer Inc. $PFE Stake Raised by Royal Fund Management LLC

Royal Fund Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 275.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,508 shares of the biopharmaceutical company’s stock after buying an additional 59,072 shares during the quarter. Royal Fund Management LLC’s holdings in Pfizer were worth $2,261,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Evolution Wealth Management Inc. raised its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the 4th quarter worth about $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC increased its stake in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Global Trust Asset Management LLC raised its holdings in Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim cut their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Stock Performance

Shares of PFE stock opened at $25.16 on Thursday. The company has a market capitalization of $143.40 billion, a price-to-earnings ratio of 19.21 and a beta of 0.35. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock’s fifty day simple moving average is $25.08 and its 200-day simple moving average is $26.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the business earned $0.92 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The European Commission granted marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026–2027 season. The approval supports continued seasonal vaccine revenue, although demand remains difficult to forecast. BioNTech and Pfizer Secure EU Approval for XFG-Adapted COVID-19 Vaccine for 2026-2027 Season
• Positive Sentiment: Québec selected Pfizer’s PREVNAR 20 for its publicly funded pediatric pneumococcal immunization program. The decision could expand vaccine adoption and provide recurring sales support in the Canadian market. Pfizer’s PREVNAR 20 Selected for Québec’s Publicly Funded Pediatric Pneumococcal Immunization Program
• Positive Sentiment: Erste Group Bank raised its fiscal 2027 Pfizer earnings estimate to $2.86 per share from $2.84. The increase, though modest, signals slightly improved confidence in the company’s future earnings trajectory. Pfizer FY2027 Earnings Estimate Update
• Neutral Sentiment: Pfizer completed a Phase 1 study evaluating formulation and dosing for ibuzatrelvir, an oral antiviral candidate. The update advances development but offers no evidence yet of efficacy or commercial approval. Pfizer Fine Tunes Ibuzatrelvir Tablet in Completed Phase 1 Study
• Neutral Sentiment: Analysts expect Pfizer to potentially beat second-quarter earnings estimates, supported by key products and cost or operational improvements. Investors are focused on whether management maintains its full-year 2026 earnings guidance of $2.80–$3.00 per share and addresses COVID-related revenue declines. Pfizer Expected to Beat Earnings Estimates
• Negative Sentiment: Investors remain cautious ahead of the earnings release because Pfizer must offset declining COVID-related sales and demonstrate progress in cancer, obesity and other growth areas. Uncertainty around guidance and the pace of its business reset may be limiting buying interest.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.